8-K: Century Therapeutics Shareholders Elect Directors and Ratify Auditor at 2025 Annual Meeting

Century Therapeutics, Inc. announced the successful election of Class I Directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Summary

• Century Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders virtually on June 12, 2025.
• As of the record date, April 16, 2025, there were 86,158,758 outstanding shares of common stock.
• Shareholders elected Daphne Quimi and Carlo Rizzuto, Ph.D. as Class I Directors to serve until the 2028 Annual Meeting of Stockholders.
• Daphne Quimi received 52,593,454 'For' votes, 4,437,555 'Withheld' votes, and 15,072,004 'Broker Non-Votes'.
• Carlo Rizzuto, Ph.D. received 51,373,990 'For' votes, 5,657,019 'Withheld' votes, and 15,072,004 'Broker Non-Votes'.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2025 fiscal year was ratified.
• The auditor ratification received 71,768,193 'For' votes, 302,484 'Against' votes, 32,336 'Abstentions', and 0 'Broker Non-Votes'.

Sentiment

Score: 7

Explanation: The successful election of directors and ratification of the independent auditor with strong shareholder support indicates stable corporate governance and routine operational approvals.

Positives

• All proposals submitted to a vote of the stockholders, including the election of Class I Directors and the ratification of the independent auditor, were approved with strong shareholder support.
• The successful ratification of Ernst & Young LLP ensures continuity in the company's financial oversight for the 2025 fiscal year.

Future Outlook

The elected Class I Directors, Daphne Quimi and Carlo Rizzuto, Ph.D., will serve until the 2028 Annual Meeting of Stockholders, providing continuity in board leadership.

Industry Context

This 8-K filing details routine corporate governance matters, specifically the outcomes of an annual shareholder meeting, which are standard practices across publicly traded companies in all industries, including biotechnology.

Corporate Governance

Stakeholder Impact

• Shareholders exercised their voting rights on key corporate governance matters, including director elections and auditor ratification.
• The election of directors impacts the strategic direction and oversight of the company on behalf of shareholders.

Next Steps

• Class I Directors Daphne Quimi and Carlo Rizzuto, Ph.D. will serve on the Board until the 2028 Annual Meeting of Stockholders.
• Ernst & Young LLP will serve as the independent registered public accounting firm for the 2025 fiscal year.

Key Dates

Keywords

Century Therapeutics, 8-K filing, Annual Meeting, Stockholders Meeting, Director Election, Auditor Ratification, Corporate Governance, SEC filing, IPSC